Published in Leuk Res Treatment on April 24, 2012
Drug resistance mediated by AEG-1/MTDH/LYRIC. Adv Cancer Res (2013) 0.95
Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int (2013) 0.93
Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? Biosci Rep (2013) 0.85
IGF-IR determines the fates of BCR/ABL leukemia. J Hematol Oncol (2015) 0.81
Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type. Cancer Sci (2014) 0.76
Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell (1986) 20.08
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med (1996) 17.51
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 8.69
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
X-linked IAP is a direct inhibitor of cell-death proteases. Nature (1997) 8.26
FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 7.50
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 6.64
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 6.62
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev (2000) 5.36
An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol (1993) 5.15
The many forks in FOXO's road. Sci STKE (2003) 4.23
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep (2006) 4.15
IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08
The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood (2002) 4.02
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (1985) 3.97
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell (1991) 3.95
Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med (2003) 3.93
The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J (2004) 3.92
The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch (2003) 3.76
Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res (2007) 3.72
Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer (2007) 3.63
Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 3.52
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J (1997) 3.34
Characterization of XIAP-deficient mice. Mol Cell Biol (2001) 3.32
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A (1997) 3.20
Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia (2005) 3.13
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature (2010) 3.12
Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev (2006) 2.95
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood (2008) 2.76
Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A (2002) 2.74
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood (2003) 2.60
Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther (2006) 2.55
Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest (2010) 2.44
Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci (2002) 2.40
P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev (1999) 2.34
XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J (2005) 2.27
A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res (2009) 2.27
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther (1997) 2.17
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (2008) 2.15
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood (2004) 2.08
Targeting XIAP for the treatment of malignancy. Cell Death Differ (2006) 2.04
Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol (2001) 2.02
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther (2002) 1.95
Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol (2011) 1.90
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia (2007) 1.89
Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci (2004) 1.87
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res (2001) 1.81
Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol (2006) 1.77
XIAP, the guardian angel. Nat Rev Mol Cell Biol (2001) 1.72
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia (2004) 1.71
NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene (2003) 1.71
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol (2004) 1.67
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Survivin study: an update of "what is the next wave"? J Cell Physiol (2006) 1.63
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol (2004) 1.63
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res (2008) 1.62
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood (1999) 1.61
The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A (1998) 1.60
XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ (2010) 1.57
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res (2008) 1.56
P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood (1994) 1.55
Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol (2005) 1.53
Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta (2011) 1.52
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia (2007) 1.52
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer (2004) 1.52
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 1.51
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res (2004) 1.47
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther (2007) 1.47
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 1.47
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med (2011) 1.45
NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res (2010) 1.45
Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther (2008) 1.44
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci (2011) 1.43
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41
FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J Biol Chem (2006) 1.40
Targeting NF-kappaB in hematologic malignancies. Cell Death Differ (2006) 1.38
A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem (2002) 1.37
Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia (2009) 1.37
High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res (2004) 1.36
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program (2009) 1.34
Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle (2004) 1.34
Cancer cells survive with survivin. Cancer Sci (2008) 1.33
Geographic variation in Epstein-Barr virus-associated Burkitt's lymphoma in children from Brazil. Int J Cancer (2004) 1.06
XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. Leuk Res (2013) 0.88
Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom (2010) 0.84
Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol (2004) 0.84
Langerhans cell histiocytosis: differences and similarities in long-term outcome of paediatric and adult patients at a single institutional centre. Hematology (2014) 0.83
P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol (2011) 0.82
Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells. Tumour Biol (2012) 0.81
Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells. Leuk Res (2012) 0.81
Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high-grade gliomas. Cancer Invest (2008) 0.80
DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. Eur J Haematol (2003) 0.80
Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation. Anticancer Drugs (2008) 0.79
Burkitt-like lymphoma in an infant: a case report. Rev Hosp Clin Fac Med Sao Paulo (2003) 0.79
Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells. Oncol Rep (2011) 0.79
Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients. Leuk Res (2013) 0.78
ABCB1 single nucleotide polymorphisms in the Brazilian population. Mol Biol Rep (2009) 0.78
ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. J Cancer Res Clin Oncol (2012) 0.78
p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome. Cytometry B Clin Cytom (2010) 0.76
Insights into apoptosis mechanisms induced by DNA-damaging agents in Burkitt's lymphoma cells. Cancer Invest (2009) 0.75
Lack of prognostic significance of survivin in pediatric medulloblastoma. Pathol Oncol Res (2011) 0.75
Centroblastic diffuse large B cell lymphoma displays distinct expression pattern and prognostic role of apoptosis resistance related proteins. Cancer Invest (2012) 0.75
Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype. Cancer Chemother Pharmacol (2008) 0.75